Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA402 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
IMA402 + pembrolizumab is an investigational combination therapy being developed by Immatics for the treatment of PRAME-positive solid tumors. IMA402 is a next-generation T-cell engaging receptor (TCER) bispecific molecule designed to target a peptide derived from the PRAME (preferentially expressed antigen in melanoma) protein presented by HLA-A*02:01. Uniquely, IMA402 utilizes mRNA-enabled technology for in vivo expression of the bispecific molecule, which redirects and activates T cells against cancer cells. Pembrolizumab (Keytruda) is a programmed death receptor-1 (PD-1) blocking monoclonal antibody that serves as an immune checkpoint inhibitor. By combining these two agents, the therapy aims to recruit T cells to the tumor site via IMA402 and simultaneously prevent their exhaustion or inhibition via pembrolizumab-mediated PD-1 blockade. The combination is currently in Phase 1 clinical development for patients with advanced melanoma, gynecologic cancers, and other solid tumors.
- Brand names
- Keytruda
- Other names
- IMA402 + pembrolizumab combination
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CD3 (T-cell surface glycoprotein CD3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on IMA402 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA402 + pembrolizumab.